Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Alpha Cognition Inc ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


NDAQ:ACOG - Post by User

Post by partystockeron Dec 26, 2021 5:38pm
270 Views
Post# 34262984

$ACOG looks like a strong buy rn

$ACOG looks like a strong buy rn

Alpha Cognition is continuing to look like a strong buy in the pre-revenue biopharma market.


$ACOG’s ALPHA-1062 belongs to a class of drugs that are currently the standard form of care for Alzheimer's. The benefit of ALPHA-1062 is that it offers effective treatment without the majority of gastrointestinal side effects brought on by other drugs in the same class. 45% of patients who discontinue the use of these acetylcholinesterase inhibitor drugs (AChEI), do so for these reasons. 


With the AChEI market being around $5 billion, capturing even a small percent of this market represents a massive opportunity for $ACOG, currently valued at $63.96 million. 


$ACOG.V has strong data on ALPHA-1062 with a low bar for approval where it requires only bioequivalence rather than efficacy. This makes its Phase 3 trial faster and smaller than typical, with a New Drug Application planned for 2022.


With some analysts speculating a $5 price target for $ACOG, that puts potential earnings at this point around 382%.


$ACOG is currently trading at $1.04 and is valued at an MCAP of $63.96 million.


https://www.cantechletter.com/2021/12/three-canadian-biopharma-stocks-for-2022/#
<< Previous
Bullboard Posts
Next >>